Table 1.
Cohort characteristics (n = 226)
| Characteristic | African American men | Non–African American men, | P a |
|---|---|---|---|
| (n = 113) | (n = 113) | ||
| Median age (IQR), y | 61 (55-67) | 65 (59-70) | .005 |
| Age group, No. (%) | .07 | ||
| Younger than 50 | 12 (11) | 5 (4.4) | |
| 50 and older | 101 (89) | 108 (96) | |
| Pretreatment PSA, ng/mL | .26 | ||
| Median (IQR) | 6.9 (5.1, 8.8) | 6.3 (4.3, 8.4) | |
| PSA categories, No. (%) | .61 | ||
| 0-6 ng/mL | 44 (39) | 51 (45) | |
| >6-10 ng/mL | 45 (40) | 42 (37) | |
| >10-20 ng/mL | 24 (21) | 20 (18) | |
| Biopsy Gleason score, No. (%) | .64 | ||
| 3 + 3 | 13 (12) | 9 (8.0) | |
| 3 + 4 | 67 (59) | 68 (60) | |
| 4 + 3 | 33 (29) | 36 (32) | |
| Median No. of positive cores (IQR) | 5 (4-7) | 6 (4-8) | .11 |
| PPB category, No. (%) | .46 | ||
| <34 | 36 (32) | 31 (27) | |
| ≥34 | 77 (68) | 82 (73) | |
| NCCN risk, No. (%) | .60 | ||
| Low risk | 11 (9.7) | 7 (6.2) | |
| Favorable risk | 37 (33) | 37 (33) | |
| Unfavorable risk | 65 (58) | 69 (61) | |
| Biopsy CAPRA, No. (%) | .91 | ||
| 0-2 | 21 (19) | 20 (18) | |
| 3-5 | 70 (62) | 73 (65) | |
| 6-10 | 22 (19) | 20 (18) | |
| Decipher (biopsy) category, No. (%)b | .62 | ||
| Low risk | 47 (42) | 46 (41) | |
| Int risk | 27 (24) | 33 (29) | |
| High risk | 39 (35) | 34 (30) | |
| Treatment type, No. (%) | .76 | ||
| Prostatectomy | 41 (36) | 41 (36) | |
| Radiation (no ADT) | 41 (36) | 47 (42) | |
| Radiation (with ADT) | 25 (22) | 21 (19) | |
| NA | 6 (5.3) | 4 (3.5) |
a
Wilcoxon rank sum test for numeric and Pearson χ2 test for categorical variables. ADT = androgen deprivation therapy; CAPRA = Cancer of the Prostate Risk Assessment; IQR = interquartile range; NA = not available; NCCN = National Comprehensive Cancer Network; PPB = positive percentage biopsy; PSA = prostate-specific antigen.
b
Decipher score is categorized as low risk (<0.45), intermediate risk (≥0.45-0.60), and high risk (>0.60).